Skip to main content
Top
Published in: European Journal of Epidemiology 12/2020

01-12-2020 | Stroke | CARDIOVASCULAR DISEASE

Annual rate of newly treated atrial fibrillation by age and gender in France, 2010–2016

Authors: Amélie Gabet, Edouard Chatignoux, Cécile Billionnet, Géric Maura, Maurice Giroud, Yannick Béjot, Valérie Olié

Published in: European Journal of Epidemiology | Issue 12/2020

Login to get access

Abstract

Few studies are available on atrial fibrillation (AF) burden at a whole country scale. The objective was to estimate the rate of AF patients newly treated with oral anticoagulants (OAC) in France each year between 2010 and 2016 and to describe age and gender differences. We used the French national health data system. For each year between 2010 and 2016, we identified patients aged over 20 initiating OAC. OAC indicated for the treatment of AF was determined by hospitalization diagnoses, specific procedures and registered long-term disease status, or a multiple imputation process for patients with no recorded information as to why they initiated OAC. Among the 421,453 individuals initiating OAC treatment in 2016, the estimated number of newly treated AF patients was 210,131, women accounting for 46%, patients under 65 years old 17%, and 21.4% of patients living in most deprived area. Age-standardized rates reached 400/100,000 inhabitants. Approximately 19% of patients were recently hospitalized for heart failure and 7% for stroke. Age-standardized rates increased by 35% over the study period in both genders, with a marked increase in patients under 55 (+ 41%) and those over 85 years old (+ 60%). Annual rates of AF patients newly treated with OAC increased by 35% between 2010 and 2016. Important differences in rates were observed according to age, gender and the deprivation level of the living area.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ruddox V, Sandven I, Munkhaugen J, et al. Atrial fibrillation and the risk for myocardial infarction, all-cause mortality and heart failure: a systematic review and meta-analysis. Eur J Prev Cardiol. 2017;24(14):1555–66.CrossRef Ruddox V, Sandven I, Munkhaugen J, et al. Atrial fibrillation and the risk for myocardial infarction, all-cause mortality and heart failure: a systematic review and meta-analysis. Eur J Prev Cardiol. 2017;24(14):1555–66.CrossRef
2.
go back to reference Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. Circulation. 2014;129(8):837–47.CrossRef Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. Circulation. 2014;129(8):837–47.CrossRef
3.
go back to reference Bejot Y, Ben Salem D, Osseby GV, et al. Epidemiology of ischemic stroke from atrial fibrillation in Dijon, France, from 1985 to 2006. Neurology. 2009;72(4):346–53.CrossRef Bejot Y, Ben Salem D, Osseby GV, et al. Epidemiology of ischemic stroke from atrial fibrillation in Dijon, France, from 1985 to 2006. Neurology. 2009;72(4):346–53.CrossRef
4.
go back to reference Steffel J, Roldan-Schilling V, Rowell N, et al. The 2018 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330–93.CrossRef Steffel J, Roldan-Schilling V, Rowell N, et al. The 2018 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330–93.CrossRef
5.
go back to reference Boriani G, Proietti M, Laroche C, et al. Contemporary stroke prevention strategies in 11 096 European patients with atrial fibrillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) Long-Term General Registry. Europace. 2018;20(5):747–57.CrossRef Boriani G, Proietti M, Laroche C, et al. Contemporary stroke prevention strategies in 11 096 European patients with atrial fibrillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) Long-Term General Registry. Europace. 2018;20(5):747–57.CrossRef
6.
go back to reference Yiin GS, Howard DP, Paul NL, et al. Recent time trends in incidence, outcome and premorbid treatment of atrial fibrillation-related stroke and other embolic vascular events: a population-based study. J Neurol Neurosurg Psychiatry. 2017;88(1):12–8.CrossRef Yiin GS, Howard DP, Paul NL, et al. Recent time trends in incidence, outcome and premorbid treatment of atrial fibrillation-related stroke and other embolic vascular events: a population-based study. J Neurol Neurosurg Psychiatry. 2017;88(1):12–8.CrossRef
7.
go back to reference Tuppin P, Rudant J, Constantinou P, et al. Value of a national administrative database to guide public decisions: from the systeme national d’information interregimes de l’Assurance Maladie (SNIIRAM) to the systeme national des donnees de sante (SNDS) in France. Rev Epidemiol Sante Publique. 2017;65(Suppl 4):S149–67.CrossRef Tuppin P, Rudant J, Constantinou P, et al. Value of a national administrative database to guide public decisions: from the systeme national d’information interregimes de l’Assurance Maladie (SNIIRAM) to the systeme national des donnees de sante (SNDS) in France. Rev Epidemiol Sante Publique. 2017;65(Suppl 4):S149–67.CrossRef
8.
go back to reference Bezin J, Duong M, Lassalle R, et al. The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2017;26(8):954–62.CrossRef Bezin J, Duong M, Lassalle R, et al. The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2017;26(8):954–62.CrossRef
9.
go back to reference Billionnet C, Alla F, Berigaud E, et al. Identifying atrial fibrillation in outpatients initiating oral anticoagulants based on medico-administrative data: results from the French national healthcare databases. Pharmacoepidemiol Drug Saf. 2017;26(5):535–43.CrossRef Billionnet C, Alla F, Berigaud E, et al. Identifying atrial fibrillation in outpatients initiating oral anticoagulants based on medico-administrative data: results from the French national healthcare databases. Pharmacoepidemiol Drug Saf. 2017;26(5):535–43.CrossRef
10.
go back to reference van Buuren S. Flexible imputation of missing data. 2nd ed. London: Chapman and Hall; 2018.CrossRef van Buuren S. Flexible imputation of missing data. 2nd ed. London: Chapman and Hall; 2018.CrossRef
11.
go back to reference Rey G, Jougla E, Fouillet A, et al. Ecological association between a deprivation index and mortality in France over the period 1997–2001: variations with spatial scale, degree of urbanicity, age, gender and cause of death. BMC Public Health. 2009;9:33.CrossRef Rey G, Jougla E, Fouillet A, et al. Ecological association between a deprivation index and mortality in France over the period 1997–2001: variations with spatial scale, degree of urbanicity, age, gender and cause of death. BMC Public Health. 2009;9:33.CrossRef
12.
go back to reference Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263–72.CrossRef Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263–72.CrossRef
13.
go back to reference Huiart L, Ferdynus C, Renoux C, et al. Trends in initiation of direct oral anticoagulant therapies for atrial fibrillation in a national population-based cross-sectional study in the French health insurance databases. BMJ Open. 2018;8(3):e018180.CrossRef Huiart L, Ferdynus C, Renoux C, et al. Trends in initiation of direct oral anticoagulant therapies for atrial fibrillation in a national population-based cross-sectional study in the French health insurance databases. BMJ Open. 2018;8(3):e018180.CrossRef
14.
go back to reference Charlemagne A, Blacher J, Cohen A, et al. Epidemiology of atrial fibrillation in France: extrapolation of international epidemiological data to France and analysis of French hospitalization data. Arch Cardiovasc Dis. 2011;104(2):115–24.CrossRef Charlemagne A, Blacher J, Cohen A, et al. Epidemiology of atrial fibrillation in France: extrapolation of international epidemiological data to France and analysis of French hospitalization data. Arch Cardiovasc Dis. 2011;104(2):115–24.CrossRef
15.
go back to reference Cotte FE, Chaize G, Gaudin AF, et al. Burden of stroke and other cardiovascular complications in patients with atrial fibrillation hospitalized in France. Europace. 2016;18(4):501–7.CrossRef Cotte FE, Chaize G, Gaudin AF, et al. Burden of stroke and other cardiovascular complications in patients with atrial fibrillation hospitalized in France. Europace. 2016;18(4):501–7.CrossRef
16.
go back to reference Fauchier L, Samson A, Chaize G, et al. Cause of death in patients with atrial fibrillation admitted to French hospitals in 2012: a nationwide database study. Open Heart. 2015;2(1):e000290.CrossRef Fauchier L, Samson A, Chaize G, et al. Cause of death in patients with atrial fibrillation admitted to French hospitals in 2012: a nationwide database study. Open Heart. 2015;2(1):e000290.CrossRef
17.
go back to reference Johansson C, Dahlqvist E, Andersson J, et al. Incidence, type of atrial fibrillation and risk factors for stroke: a population-based cohort study. Clin Epidemiol. 2017;9:53–62.CrossRef Johansson C, Dahlqvist E, Andersson J, et al. Incidence, type of atrial fibrillation and risk factors for stroke: a population-based cohort study. Clin Epidemiol. 2017;9:53–62.CrossRef
18.
go back to reference Wilke T, Groth A, Mueller S, et al. Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients. Europace. 2013;15(4):486–93.CrossRef Wilke T, Groth A, Mueller S, et al. Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients. Europace. 2013;15(4):486–93.CrossRef
19.
go back to reference Piccini JP, Hammill BG, Sinner MF, et al. Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries, 1993–2007. Circul Cardiovasc Qual Outcomes. 2012;5(1):85–93.CrossRef Piccini JP, Hammill BG, Sinner MF, et al. Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries, 1993–2007. Circul Cardiovasc Qual Outcomes. 2012;5(1):85–93.CrossRef
20.
go back to reference Heeringa J, van der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006;27(8):949–53.CrossRef Heeringa J, van der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006;27(8):949–53.CrossRef
21.
go back to reference Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114(2):119–25.CrossRef Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114(2):119–25.CrossRef
22.
go back to reference Schnabel RB, Yin X, Gona P, et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet (Lond Engl). 2015;386(9989):154–62.CrossRef Schnabel RB, Yin X, Gona P, et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet (Lond Engl). 2015;386(9989):154–62.CrossRef
23.
go back to reference Stefansdottir H, Aspelund T, Gudnason V, et al. Trends in the incidence and prevalence of atrial fibrillation in Iceland and future projections. Europace. 2011;13(8):1110–7.CrossRef Stefansdottir H, Aspelund T, Gudnason V, et al. Trends in the incidence and prevalence of atrial fibrillation in Iceland and future projections. Europace. 2011;13(8):1110–7.CrossRef
24.
go back to reference Barra S, Fynn S. Untreated atrial fibrillation in the United Kingdom: understanding the barriers and treatment options. J Saudi Heart Assoc. 2015;27(1):31–43.CrossRef Barra S, Fynn S. Untreated atrial fibrillation in the United Kingdom: understanding the barriers and treatment options. J Saudi Heart Assoc. 2015;27(1):31–43.CrossRef
25.
go back to reference Gadsboll K, Staerk L, Fosbol EL, et al. Increased use of oral anticoagulants in patients with atrial fibrillation: temporal trends from 2005 to 2015 in Denmark. Eur Heart J. 2017;38(12):899–906.PubMed Gadsboll K, Staerk L, Fosbol EL, et al. Increased use of oral anticoagulants in patients with atrial fibrillation: temporal trends from 2005 to 2015 in Denmark. Eur Heart J. 2017;38(12):899–906.PubMed
26.
go back to reference Lacoin L, Lumley M, Ridha E, et al. Evolving landscape of stroke prevention in atrial fibrillation within the UK between 2012 and 2016: a cross-sectional analysis study using CPRD. BMJ Open. 2017;7(9):e015363.CrossRef Lacoin L, Lumley M, Ridha E, et al. Evolving landscape of stroke prevention in atrial fibrillation within the UK between 2012 and 2016: a cross-sectional analysis study using CPRD. BMJ Open. 2017;7(9):e015363.CrossRef
27.
go back to reference Camm AJ, Accetta G, Ambrosio G, et al. Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. Heart. 2017;103(4):307–14.CrossRef Camm AJ, Accetta G, Ambrosio G, et al. Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. Heart. 2017;103(4):307–14.CrossRef
28.
go back to reference Steinberg BA, Gao H, Shrader P, et al. International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries. Am Heart J. 2017;194:132–40.CrossRef Steinberg BA, Gao H, Shrader P, et al. International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries. Am Heart J. 2017;194:132–40.CrossRef
29.
go back to reference Magnussen C, Niiranen TJ, Ojeda FM, et al. Sex differences and similarities in atrial fibrillation epidemiology, risk factors, and mortality in community cohorts: results From the BiomarCaRE Consortium (Biomarker for Cardiovascular Risk Assessment in Europe). Circulation. 2017;136(17):1588–97.PubMedPubMedCentral Magnussen C, Niiranen TJ, Ojeda FM, et al. Sex differences and similarities in atrial fibrillation epidemiology, risk factors, and mortality in community cohorts: results From the BiomarCaRE Consortium (Biomarker for Cardiovascular Risk Assessment in Europe). Circulation. 2017;136(17):1588–97.PubMedPubMedCentral
30.
go back to reference Sabouret P, Depret-Bixio L, Cotte FE, et al. Sex differences in stroke prevention in atrial fibrillation in French primary care. Results of the AFIGP (Atrial Fibrillation In General Practice) database. Clin Res Cardiol. 2014;103(11):887–93.CrossRef Sabouret P, Depret-Bixio L, Cotte FE, et al. Sex differences in stroke prevention in atrial fibrillation in French primary care. Results of the AFIGP (Atrial Fibrillation In General Practice) database. Clin Res Cardiol. 2014;103(11):887–93.CrossRef
31.
go back to reference Hsu JC, Maddox TM, Kennedy K, et al. Aspirin instead of oral anticoagulant prescription in atrial fibrillation patients at risk for stroke. J Am Coll Cardiol. 2016;67(25):2913–23.CrossRef Hsu JC, Maddox TM, Kennedy K, et al. Aspirin instead of oral anticoagulant prescription in atrial fibrillation patients at risk for stroke. J Am Coll Cardiol. 2016;67(25):2913–23.CrossRef
32.
go back to reference Thompson LE, Maddox TM, Lei L, et al. Sex Differences in the use of oral anticoagulants for atrial fibrillation: a report from the national cardiovascular data registry (NCDR(®)) PINNACLE registry. J Am Heart Assoc. 2017;6(7):e005801.CrossRef Thompson LE, Maddox TM, Lei L, et al. Sex Differences in the use of oral anticoagulants for atrial fibrillation: a report from the national cardiovascular data registry (NCDR(®)) PINNACLE registry. J Am Heart Assoc. 2017;6(7):e005801.CrossRef
33.
go back to reference Savelieva I, Camm AJ. Female gender as a risk factor for stroke associated with atrial fibrillation. Eur Heart J. 2017;38(19):1480–4.CrossRef Savelieva I, Camm AJ. Female gender as a risk factor for stroke associated with atrial fibrillation. Eur Heart J. 2017;38(19):1480–4.CrossRef
34.
go back to reference Sjölander M, Eriksson M, Asplund K, et al. Socioeconomic inequalities in the prescription of oral anticoagulants in stroke patients with atrial fibrillation. Stroke. 2015;46(8):2220–5.CrossRef Sjölander M, Eriksson M, Asplund K, et al. Socioeconomic inequalities in the prescription of oral anticoagulants in stroke patients with atrial fibrillation. Stroke. 2015;46(8):2220–5.CrossRef
35.
go back to reference Raparelli V, Proietti M, Butta C, et al. Medication prescription and adherence disparities in non valvular atrial fibrillation patients: an Italian portrait from the ARAPACIS study. Intern Emerg Med. 2014;9(8):861–70.CrossRef Raparelli V, Proietti M, Butta C, et al. Medication prescription and adherence disparities in non valvular atrial fibrillation patients: an Italian portrait from the ARAPACIS study. Intern Emerg Med. 2014;9(8):861–70.CrossRef
36.
go back to reference Jain V, Marshall IJ, Crichton SL, et al. Trends in the prevalence and management of pre-stroke atrial fibrillation, the South London Stroke Register, 1995–2014. PLoS ONE. 2017;12(4):e0175980–e80.CrossRef Jain V, Marshall IJ, Crichton SL, et al. Trends in the prevalence and management of pre-stroke atrial fibrillation, the South London Stroke Register, 1995–2014. PLoS ONE. 2017;12(4):e0175980–e80.CrossRef
37.
go back to reference Zoller B, Li X, Sundquist J, et al. Neighbourhood deprivation and hospitalization for atrial fibrillation in Sweden. Europace. 2013;15(8):1119–27.CrossRef Zoller B, Li X, Sundquist J, et al. Neighbourhood deprivation and hospitalization for atrial fibrillation in Sweden. Europace. 2013;15(8):1119–27.CrossRef
Metadata
Title
Annual rate of newly treated atrial fibrillation by age and gender in France, 2010–2016
Authors
Amélie Gabet
Edouard Chatignoux
Cécile Billionnet
Géric Maura
Maurice Giroud
Yannick Béjot
Valérie Olié
Publication date
01-12-2020
Publisher
Springer Netherlands
Published in
European Journal of Epidemiology / Issue 12/2020
Print ISSN: 0393-2990
Electronic ISSN: 1573-7284
DOI
https://doi.org/10.1007/s10654-019-00594-3

Other articles of this Issue 12/2020

European Journal of Epidemiology 12/2020 Go to the issue